Full-Text Search:
Home|About CNKI|User Service|中文
Add to Favorite Get Latest Update

Clinical observation of bortezomib in treatment of multiple myeloma

ZHU Lei,GUO Jingming,SHANG Anfang,LI Ping,LEI Dongmei(Internal Medicine of Hematology,The Central People's Hospital in Yichang,The First College of Clinical Medical Science of Three Gorges University,Hubei Province, Yichang 443003,China)  
AIM To investigate clinical efficacy and adverse drug reaction(ADR)of bortezomib in treatment of multiple myeloma.METHODS Totally 62 patients with multiple myeloma were selected from our hospital during Feruary 2004 to May 2011 and divided into 2 groups.Treatment group received bortezomib and dexamethasone(n = 38)and control group received vincristine,adriamycin and dexamethasone(VAD)(n = 24).RESULTS The complete remission (CR)rates were 39.4%for treatment group and 20.8%for control group,respectively.The total effective rates(TERs)of treatment group and control group were 81.6%and 58.3%,respectively.The rates of peripheral neuropathy in the clinic were 34.2%and 37.5%,respectively.The rates of thombocytopenia in the clinic were 28.9%and 20.8%respectively. The rates of infection in the clinic were 10.5%and 8.3%,respectively.There were statistical significances in the difference of TERs between 2 groups(P0.05),while there was no statistical significance in incidence of ADR between 2 groups(P0.05).CONCLUSION Bortezomib can be effective for the treatment of multiple myeloma.
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©CNKI All Rights Reserved